NISPA

Nijmegen Institute for Scientist-Practitioners in Addiction

Baclofen as relapse prevention in the treatment of gamma-hydroxybutyrate dependence: a case series.

TitelBaclofen as relapse prevention in the treatment of gamma-hydroxybutyrate dependence: a case series.
PublicatietypeJournal Article
Jaar van publicatie2015
AuteursKamal RM, Loonen AJ, Dijkstra BAG, DeJong CA
UitgaveJ Clin Psychopharmacol
Volume35
Nummer3
Pagina's313-8
Publicatiedatum2015 Jun
ISSN1533-712X
Samenvatting

In the last decade, gamma-hydroxybutyrate (GHB) abuse and dependence have increased. It has been reported that GHB dependence has a high rate of relapse, serious complications of intoxication, and a potentially life-threatening withdrawal syndrome. Nevertheless, in clinical practice, there is no known medical treatment to support GHB relapse prevention. We describe a case series of patients who were supported through an off-label treatment with baclofen to avoid a relapse into GHB abuse, for a period of 12 weeks. Nine of 11 patients did not relapse while taking a dose ranging from 30 to 60 mg per day, one patient relapsed after 5 weeks, and one stopped after 7 weeks. Baclofen was well tolerated; patients reported mild side effects such as fatigue, nausea, dry mouth, excessive sweating, and depressive feelings. Although systematic evidence is still lacking, our practice-based experience suggests that treatment with baclofen to assist abstinence might be effective in patients with GHB dependence. Further systematic controlled studies are necessary to establish the exact efficacy and safety of baclofen as relapse prevention for GHB-dependent patients.

DOI10.1097/JCP.0000000000000315
Alternatieve uitgaveJ Clin Psychopharmacol
PubMed ID25900349